Although oral hormonal therapy is known to substantially reduce breast cancer recurrence in women with hormone receptor-positive tumors, about one-half of patients fail to take their medications as directed. A new study by Columbia University Medical Center (CUMC) researchers has found that the introduction of generic aromatase inhibitors (the most common type of hormone therapy), which are considerably less expensive than their brand name counterparts, increased treatment adherence by 50 percent.

The study was published today in the online issue of Journal of the National Cancer Institute.

READ FULL ARTICLE Curated publisher From News Medical